Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13844347 | 0.83 | HTT (0.36) | HTTKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL16276064 | 0.83 | HTT (0.36) | HTTKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL9449998 | 0.83 | PIK3CG (0.34) | PIK3CGIDH1 | |
| SCHEMBL10147793 | 0.83 | PIK3CG (0.34) | PIK3CGIDH1 | |
| SCHEMBL15114573 | 0.83 | HTT (0.36) | HTTKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL5170535 | 0.83 | HTT (0.36) | HTTKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL20049385 | 0.83 | PIK3CG (0.34) | PIK3CGIDH1 | |
| SCHEMBL21180509 | 0.80 | PIK3CG (0.35) | PIK3CGIDH1 | |
| SCHEMBL15114575 | 0.80 | HTT (0.37) | HTTKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL14213299 | 0.79 | PIK3CG (0.33) | PIK3CGIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814384-B2 | Inhibtors of Raf kinases | KINNATE BIOPHARMA INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814384-B2 | Inhibtors of Raf kinases | KINNATE BIOPHARMA INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230339944-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | Oppilan Pharma Limited (GB) | 2023-10-26 | — | — | US | disclosed |
| WO-2023150681-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150394-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| WO-2022261296-A1 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-12-15 | — | — | WO | disclosed |
| US-11358956-B2 | Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2022-06-14 | — | — | US | disclosed |
| US-20210188825-A1 | COMPOUNDS CONTAINING POLYSUBSTITUTED BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2021-06-24 | — | — | US | disclosed |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100234435-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | BHATTACHARYA SAMIT K | 2010-09-16 | — | — | US | disclosed |
| US-20100234435-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | BHATTACHARYA SAMIT K | 2010-09-16 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100041721-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
| US-7531556-B2 | Compositions useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-12 | — | — | US | disclosed |
| US-7514434-B2 | Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070004723-A1 | Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof | MIDCAP FINANCIAL TRUST | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | BRS3, GPR119, GIPR | HTT 3120/4885PIK3CG 2665/4885IDH1 4843/4885 |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | ABCG2, CYP4F8, CYP3A5 | HTT 3406/4885PIK3CG 1651/4885IDH1 2372/4885 |
| US-20100041721-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, SHBG, IGF1R | HTT 1662/4885PIK3CG 973/4885IDH1 119/4885 |
| US-20100234435-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | CCNI, CCNA1, PCNA | HTT 502/4885PIK3CG 2150/4885IDH1 1047/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | HTT 4444/4885PIK3CG 565/4885IDH1 322/4885 |
| US-20070004723-A1 | Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof | HAVCR2, PCNA, HCCS | HTT 1807/4885PIK3CG 2154/4885IDH1 11/4885 |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | HTT 2614/4885PIK3CG 102/4885IDH1 2259/4885 |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | HTT 3860/4885PIK3CG 3417/4885IDH1 3928/4885 |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, NSUN2 | HTT 4592/4885PIK3CG 550/4885IDH1 204/4885 |
| US-20210188825-A1 | COMPOUNDS CONTAINING POLYSUBSTITUTED BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119 | GPR119, GPR27, GCGR | HTT 2484/4885PIK3CG 2618/4885IDH1 2797/4885 |
| US-11358956-B2 | Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | GPR119, GPR27, GCGR | HTT 2484/4885PIK3CG 2618/4885IDH1 2797/4885 |
| US-20230339944-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, FH, TPMT | HTT 147/4885PIK3CG 4011/4885IDH1 26/4885 |
| US-11814384-B2 | Inhibtors of Raf kinases | RAF1, BRAF, ARAF | HTT 3374/4885PIK3CG 199/4885IDH1 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.